Respiratory Syncytial Virus (RSV) Vaccination Coverage and Intent for Vaccination, Adults 75 Years and Older and Adults 60–74 Years with High-Risk Conditions*, United States

RSV Vaccination Coverage and Intent, Adults 60+

Weekly estimates of RSV vaccination coverage and intent for vaccination among adults 60 years and older are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM). The NIS-ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older.

In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.

The NIS–ACM data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel. This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.

• Figure 1A. Cumulative Percentage of Adults 75 Years and Older and Adults 60–74 Years with High-Risk Conditions Ever Vaccinated with RSV Vaccine, 2024─25*^{,†,‡,§,^}. Data Source: National Immunization Survey–Adult COVID Module.
• Figure 1B. Weekly Intent^± for Vaccination and Cumulative Percentage of Adults 75 Years and Older and Adults 60–74 Years with High-Risk Conditions Ever Vaccinated with RSV Vaccine, 2024–25*^{,†,‡,§,^}. Data Source: National Immunization Survey–Adult COVID Module.
  • View and Download Data for Figs. 1A & 1B
• Figure 1C. Weekly Cumulative Coverage of Ever Receiving a Dose of RSV Vaccine by Jurisdiction, Adults 75 Years and Older and Adults 60–74 Years with High-Risk Conditions, United States*^,†,‡,§. Data Source: National Immunization Survey–Adult COVID Module.
  • View and Download Data for Fig. 1C
• Figure 1D. Differences in Cumulative Coverage of Ever Receiving a Dose of RSV Vaccine by Selected Demographics, Adults 75 Years and Older and Adults 60–74 Years with High-Risk Conditions, United States*^{,†,‡,§,^}. Data Source: National Immunization Survey–Adult COVID Module.
  • View and Download Data for Fig. 1D

^{Note: Confidence Intervals (CIs) describe the level of uncertainty around an estimate because a sample was taken. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% confidence interval, if the sampling method is repeated many times, the true value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.}

^{Estimates from the NIS–ACM may differ from estimates based on other data sources, and in addition to random error associated with taking a sample, are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self-reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.}

^{*CDC recommends a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease (Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR (cdc.gov)). High-risk conditions for RSV included in NIS are: chronic lung diseases, persons with diabetes reporting they use insulin, heart conditions, immunocompromised state (weakened immune system), solid organ or blood stem cell transplant (including bone marrow transplant), cancer, liver disease, sickle cell disease or thalassemia, living in a nursing home.}

^{†National estimates include 50 states, Washington D.C., Guam, and Puerto Rico. The Office of Intergovernmental and External Affairs hosts 10 Regional Offices that directly serve state and local organizations; information about Regions and which states are included in each region is available.}

^{‡Vaccination coverage estimates are based on all interviews through the current week and represent approximately the cumulative percent vaccinated by mid-week. Each week, estimates for prior weeks are recalculated using the additional interviews conducted that week (combined with all previous interviews).}

^{§Cumulative vaccination coverage estimates are suppressed when the cumulative sample size is <30 or current week sample size is <5. Vaccination intent estimates for a given week are suppressed when the sample size for that week is <30.}

^{±Estimates for vaccination intent are based on interviews conducted during that week and are adjusted to the cumulative vaccination coverage estimate for that week.}

^{^The 'Multiple or Other Races, Non-Hispanic' category includes non-Hispanic persons who selected multiple races or a race other than American Indian/Alaskan Native, Asian, Black, Native Hawaiian or other Pacific Islander, or White.}